Stockreport

LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program

LB Pharmaceuticals Inc  (LBRX) 
PDF Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE N [Read more]